Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
DNA

DNA - Ginkgo Bioworks Holdings, Inc. Stock Price, Fair Value and News

$8.69-0.23 (-2.58%)
Delayed as of 22 Oct 2024, 10:06 am ET
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

DNA Price Action

Last 7 days

22.8%


Last 30 days

11.6%


Last 90 days

-25.7%


Trailing 12 Months

-85.8%

DNA RSI Chart

AprJulOct020406080

DNA Valuation

Market Cap

18.3B

Price/Earnings (Trailing)

-20.42

Price/Sales (Trailing)

99.43

EV/EBITDA

-21.11

Price/Free Cashflow

-52.88

DNA Price/Sales (Trailing)

2022202320240100200300400500600

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DNA Fundamentals

DNA Revenue

Revenue (TTM)

184.3M

Rev. Growth (Yr)

-30.24%

Rev. Growth (Qtr)

48.13%

20202021202220232024100M200M300M400M500M

DNA Earnings

Earnings (TTM)

-897.7M

Earnings Growth (Yr)

-25.31%

Earnings Growth (Qtr)

-30.9%

20202021202220232024-4B-3B-2B-1B0

DNA Profitability

EBT Margin

-486.98%

Return on Equity

-107.76%

Return on Assets

-55.23%

Free Cashflow Yield

-1.89%

DNA Investor Care

Shares Dilution (1Y)

6.28%

Diluted EPS (TTM)

-18.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
20202021202220232024100M200M300M400M500M
Net sales
YearQ1Q2Q3Q4
2024208.7M184.3M00
2023390.0M326.0M315.0M251.5M
2022438.1M539.1M527.9M477.7M
2021136.0M195.2M254.5M313.8M
20200065.4M76.7M
201900054.2M
DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEginkgobioworks.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES1292

Ginkgo Bioworks Holdings, Inc. Frequently Asked Questions


What is the ticker symbol for Ginkgo Bioworks Holdings, Inc.? What does DNA stand for in stocks?

DNA is the stock ticker symbol of Ginkgo Bioworks Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ginkgo Bioworks Holdings, Inc. (DNA)?

As of Mon Oct 21 2024, market cap of Ginkgo Bioworks Holdings, Inc. is 18.33 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DNA stock?

You can check DNA's fair value in chart for subscribers.

Is Ginkgo Bioworks Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether DNA is over valued or under valued. Whether Ginkgo Bioworks Holdings, Inc. is cheap or expensive depends on the assumptions which impact Ginkgo Bioworks Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DNA.

What is Ginkgo Bioworks Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Oct 21 2024, DNA's PE ratio (Price to Earnings) is -20.42 and Price to Sales (PS) ratio is 99.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DNA PE ratio will change depending on the future growth rate expectations of investors.